CADL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Candel Therapeutics Inc (CADL) is not a strong buy for a beginner long-term investor at this moment. The stock lacks clear positive momentum, and its financials and technical indicators do not suggest an immediate entry point. Given the investor's impatience and preference for long-term investment, waiting for more favorable conditions or stronger signals is advisable.
The MACD histogram is negative (-0.0697) and contracting, indicating weak momentum. RSI is neutral at 36.898, and moving averages are converging, showing no clear trend. The stock is trading near its pivot point of 5.393, with resistance at 5.867 and support at 4.92. Overall, the technical indicators suggest a neutral outlook.
The company recently raised $100 million through a public offering to fund cancer therapy commercialization and ongoing trials, which could support long-term growth.
The stock fell 11.76% following the public offering announcement, reflecting negative market sentiment. Financial performance remains weak, with no revenue, a negative net income of -$11.27M (Q3 2025), and declining EPS (-36.36% YoY).
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$11.27M (improved by 5.85% YoY), and a significant EPS decline (-36.36% YoY). Gross margin remains at 0%. Overall, financials are weak and do not support a strong buy recommendation.
No recent analyst ratings or price target changes are available for CADL.
